510(k) Report

510(k) · Cleared

Cleared

Biotest Anti-Ebv Recombinant, EA Igm

K983842510(k) TraditionalCleared Jun 9, 1999222-day reviewClass I21 CFR 866.3235

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Biotest Diagnostics Corp. · LSE Epstein-Barr Virus, Other

Cleared on Jun 9, 1999 as substantially equivalent to K822734 (Gull Laboratories, Inc., 1982) after a 222-day review. Its family tree reaches back 1 generation to 1982.

Decided
Jun 9, 1999
Review
222 days
Class
Class I
Product code
LSE
Recalls
None
Predicates
1

Its longest line of descent runs back 1 generation to K822734 (1982). No later device cites it as a predicate yet.

K822734 · Ebv Igm Test · Gull Laboratories, Inc. · 198219801985199019952000
K822734 · Ebv Igm Test · Gull Laboratories, Inc. · 19820
  1. Root · 1 generation backK822734 Ebv Igm TestGull Laboratories, Inc. · 1982
  2. This deviceK983842 Biotest Anti-Ebv Recombinant, EA IgmBiotest Diagnostics Corp. · 1999
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−1K822734Ebv Igm TestGull Laboratories, Inc.1982—
0 (this device)K983842Biotest Anti-Ebv Recombinant, EA IgmBiotest Diagnostics Corp.1999—
FIG. 1 — Lineage of K983842, 1982–1999Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in LSE? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new LSE device

  1. #1 K233606 ADVIA Centaur EBV-VCA IgMscore 8.1 · 2 generations · no Class I recall
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K822734Ebv Igm Test
Summary page 2
…EBV EA IgM Classification Name: Epstein-Barr virus serological reagents Legally Marketed Device Biotest Diagnostics claims substantial equivalence to the EBV IgM Test (K822734) currently in commercial distribution by Gull Laboratories, Inc., Salt Lake City, UT. . Device Description Using recombinant DN…
Gull Laboratories, Inc.1982—

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Its one ancestor has no recall.

How does its category compare?

All LSE devices

LSE Epstein-Barr Virus, Other: FDA decisions, review times, recalls and adverse event reports over 20 years.

FDA decisions per year · LSE

1in 2024

2008: 12009: 12017: 22024: 12026 (partial year): 2
2007high 2 (2017) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · LSE

Too few LSE 510(k)s in any year since 2007 to give a median.

Recalls per year · LSE

1in 2025

2007: 22008: 12011: 12025: 1
2007high 2 (2007) · low 0 (2009)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · LSE

1in 2014

2014: 1
2007high 1 (2014) · low 0 (2007)2025

MAUDE reports naming product code LSE, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—20
20081—10
20091—00
20100—00
20110—10
20120—00
20130—00
20140—01
20150—00
20160—00
20172—00
20180—00
20190—00
20200—00
20210—00
20220—00
20230—00
20241—00
20250—10
20262—0—

What is it indicated for?

The Biotest EA IgM is an enzyme immunoassay for the detection of IgM antibodies to the Epstein-Barr Virus (EBV-EA (Early Antigens) p54/p138) in human serum or plasma.

It is indicated for use, in conjunction with other clinical and patient data obtained in assays for other Epstein-Barr antigens such as EBNA IgG and Early Antigen IgG, in the serological diagnosis of EBV infection.

Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.

Cite this page

510(k) Report. “K983842: Biotest Anti-Ebv Recombinant, EA Igm.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K983842

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026